Intravesical Therapy of Superficial Urothelial Bladder Cancer with BCG and Epirubicin 50 Mg - Comparative Analysis
, , , , oraz
13 lip 2022
O artykule
Data publikacji: 13 lip 2022
Zakres stron: 70 - 73
Otrzymano: 18 sty 2022
Przyjęty: 11 maj 2022
DOI: https://doi.org/10.2478/jbcr-2022-0009
Słowa kluczowe
© 2022 Nikolay I. Nikolov et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Bladder cancer is a heterogeneous disease in molecular, histological and clinical aspects. Treatment should also be considered from different angles - surgery, intravesical chemo- or immunotherapy, radiation therapy and lifestyle changes. Intravesical treatment of superficial bladder cancer with Еpirubicin or Bacillus Calmette-Guérin (BCG) is a continuation of surgical treatment to reduce or eliminate further recurrence.